These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 20100549)

  • 21. Chronic treatment with the mGlu5R antagonist MPEP reduces the functional effects of the mGlu5R agonist CHPG in the striatum of 6-hydroxydopamine-lesioned rats: possible relevance to the effects of mGlu5R blockade in Parkinson's disease.
    Domenici MR; Potenza RL; Martire A; Coccurello R; Pèzzola A; Reggio R; Tebano MT; Popoli P
    J Neurosci Res; 2005 Jun; 80(5):646-54. PubMed ID: 15880742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats.
    Yamamoto N; Soghomonian JJ
    Neuroscience; 2009 Nov; 163(4):1171-80. PubMed ID: 19660528
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates.
    Morin N; Grégoire L; Morissette M; Desrayaud S; Gomez-Mancilla B; Gasparini F; Di Paolo T
    Neuropharmacology; 2013 Mar; 66():355-64. PubMed ID: 22884464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urinary 8-OHdG elevations in a partial lesion rat model of Parkinson's disease correlate with behavioral symptoms and nigrostriatal dopaminergic depletion.
    Kikuchi Y; Yasuhara T; Agari T; Kondo A; Kuramoto S; Kameda M; Kadota T; Baba T; Tajiri N; Wang F; Tayra JT; Liang H; Miyoshi Y; Borlongan CV; Date I
    J Cell Physiol; 2011 May; 226(5):1390-8. PubMed ID: 20945350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Role of Group II Metabotropic Glutamate Receptors in the Striatum in Electroacupuncture Treatment of Parkinsonian Rats.
    Jia YJ; Deng JH; Zhang WZ; Sun ZL; Yang J; Yu Y; Gong XL; Jia J; Wang XM
    CNS Neurosci Ther; 2017 Jan; 23(1):23-32. PubMed ID: 27412260
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unilateral Intrastriatal 6-Hydroxydopamine Lesion in Mice: A Closer Look into Non-Motor Phenotype and Glial Response.
    Mendes-Pinheiro B; Soares-Cunha C; Marote A; Loureiro-Campos E; Campos J; Barata-Antunes S; Monteiro-Fernandes D; Santos D; Duarte-Silva S; Pinto L; José Salgado A
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768962
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease.
    McCoy MK; Martinez TN; Ruhn KA; Szymkowski DE; Smith CG; Botterman BR; Tansey KE; Tansey MG
    J Neurosci; 2006 Sep; 26(37):9365-75. PubMed ID: 16971520
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration.
    Tristão FS; Lazzarini M; Martin S; Amar M; Stühmer W; Kirchhoff F; Gomes LA; Lanfumey L; Prediger RD; Sepulveda JE; Del-Bel EA; Raisman-Vozari R
    Neurotox Res; 2016 Apr; 29(3):364-80. PubMed ID: 26403659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats.
    Lopez S; Turle-Lorenzo N; Johnston TH; Brotchie JM; Schann S; Neuville P; Amalric M
    Neuropharmacology; 2008 Sep; 55(4):483-90. PubMed ID: 18625257
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of four pyridine analogs to characterize 6-OHDA-induced modulation of mGluR5 function in rat brain using microPET studies.
    Zhu A; Wang X; Yu M; Wang JQ; Brownell AL
    J Cereb Blood Flow Metab; 2007 Sep; 27(9):1623-31. PubMed ID: 17299451
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of the metabotropic glutamate antagonist MPEP on striatal expression of the Homer family proteins in levodopa-treated hemiparkinsonian rats.
    Jiménez A; Bonastre M; Aguilar E; Marin C
    Psychopharmacology (Berl); 2009 Oct; 206(2):233-42. PubMed ID: 19636538
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of subthalamic nucleus or entopeduncular nucleus lesion on levodopa-induced neurochemical changes within the basal ganglia and on levodopa-induced motor alterations in 6-hydroxydopamine-lesioned rats.
    Périer C; Marin C; Jimenez A; Bonastre M; Tolosa E; Hirsch EC
    J Neurochem; 2003 Sep; 86(6):1328-37. PubMed ID: 12950442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
    Pinna A; Tronci E; Schintu N; Simola N; Volpini R; Pontis S; Cristalli G; Morelli M
    Neuropharmacology; 2010 Mar; 58(3):613-23. PubMed ID: 19951715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blockade of mGluR5 reverses abnormal firing of subthalamic nucleus neurons in 6-hydroxydopamine partially lesioned rats.
    Chen L; Liu J; Ali U; Gui ZH; Wang Y; Wang T; Hou C; Fan LL
    Chin J Physiol; 2011 Oct; 54(5):303-9. PubMed ID: 22135908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
    Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
    Dekundy A; Pietraszek M; Schaefer D; Cenci MA; Danysz W
    Brain Res Bull; 2006 Apr; 69(3):318-26. PubMed ID: 16564428
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adhesion molecules as potential targets for neuroprotection in a rodent model of Parkinson's disease.
    Armentero MT; Levandis G; Bazzini E; Cerri S; Ghezzi C; Blandini F
    Neurobiol Dis; 2011 Sep; 43(3):663-8. PubMed ID: 21684338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Response of colonic motility to dopaminergic stimulation is subverted in rats with nigrostriatal lesion: relevance to gastrointestinal dysfunctions in Parkinson's disease.
    Levandis G; Balestra B; Siani F; Rizzo V; Ghezzi C; Ambrosi G; Cerri S; Bonizzi A; Vicini R; Vairetti M; Ferrigno A; Pastoris O; Blandini F
    Neurogastroenterol Motil; 2015 Dec; 27(12):1783-95. PubMed ID: 26433214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peripheral inflammation and neuroprotection: systemic pretreatment with complete Freund's adjuvant reduces 6-hydroxydopamine toxicity in a rodent model of Parkinson's disease.
    Armentero MT; Levandis G; Nappi G; Bazzini E; Blandini F
    Neurobiol Dis; 2006 Dec; 24(3):492-505. PubMed ID: 17023164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
    Battaglia G; Busceti CL; Molinaro G; Biagioni F; Storto M; Fornai F; Nicoletti F; Bruno V
    J Neurosci; 2004 Jan; 24(4):828-35. PubMed ID: 14749427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.